Inclusion Criteria:  Patients voluntarily signed informed consent; Aged >18, male or female; Patients diagnosed with solid tumors confirmed by histopathology or cytology test; At least two measurable solid lesions has been examined by 18F-FDG PET/CT (RECIST1.1 standard); Patients with biopsy-proven fibronectin ED-B positive; ECOG score ≤ 0~3; Life expectancy of at least 3 months; Women of childbearing age are required to receive serum pregnancy tests, and only those who have a negative pregnancy test for eligible subjects; ALT, AST shall not exceed 3 times of the normal upper limit; Bun, Cr not exceed 1.5 times of the normal upper limit; Other routine examinations are within the normal range or considered acceptable by the researchers.  Exclusion Criteria:  Recovery from major trauma (including surgery) within 4 weeks prior to study treatment; Patients with systemic or locally severe infections, or other serious coexisting diseases; Patients with allergies or allergies to any component of the imaging agent or antibody; Patients who cannot perform PET/CT imaging scan; Patients with abnormal immune function or who have recently used immunosuppressive or potentiating agents including various vaccines; Patients with autoimmune diseases, including rheumatoid arthritis; Inadequate control of arrhythmias, including atrial fibrillation; Uncontrolled hypertension; Syphilis, HBV, HCV, or HIV positive subjects; Male and female subjects of reproductive age cannot take effective contraceptive measures; Pregnant or lactating women; Patients with a history of mental illness or related conditions; Other subjects considered unsuitable by researchers.